• Je něco špatně v tomto záznamu ?

Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging

J. Krell-Roesch, M. Rakusa, JA. Syrjanen, AC. van Harten, VJ. Lowe, CR. Jack, WK. Kremers, DS. Knopman, GB. Stokin, RC. Petersen, M. Vassilaki, YE. Geda

. 2023 ; 19 (10) : 4498-4506. [pub] 20220209

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001202

Grantová podpora
K01 MH068351 NIMH NIH HHS - United States
R01 AG041851 NIA NIH HHS - United States
R01 AG069453 NIA NIH HHS - United States
R01 AG034676 NIA NIH HHS - United States
P50 AG016574 NIA NIH HHS - United States
R01 AG011378 NIA NIH HHS - United States
R33 AG058738 NIA NIH HHS - United States
R01 NS097495 NINDS NIH HHS - United States
R01 AG057708 NIA NIH HHS - United States
P30 AG019610 NIA NIH HHS - United States
U01 AG006786 NIA NIH HHS - United States
R01 AG057708 NIA NIH HHS - United States
U01 AG006786 NIA NIH HHS - United States
P50 AG016574 NIA NIH HHS - United States
R01 AG034676 NIA NIH HHS - United States
R01 AG011378 NIA NIH HHS - United States
R01 AG041851 NIA NIH HHS - United States

INTRODUCTION: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. METHODS: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). RESULTS: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q-assessed anxiety, apathy, and nighttime behavior. DISCUSSION: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001202
003      
CZ-PrNML
005      
20240213094433.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/alz.12557 $2 doi
035    __
$a (PubMed)35142047
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Krell-Roesch, Janina $u Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA $u Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany
245    10
$a Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging / $c J. Krell-Roesch, M. Rakusa, JA. Syrjanen, AC. van Harten, VJ. Lowe, CR. Jack, WK. Kremers, DS. Knopman, GB. Stokin, RC. Petersen, M. Vassilaki, YE. Geda
520    9_
$a INTRODUCTION: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. METHODS: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). RESULTS: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q-assessed anxiety, apathy, and nighttime behavior. DISCUSSION: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a Alzheimerova nemoc $x mozkomíšní mok $7 D000544
650    _2
$a amyloidní beta-protein $x mozkomíšní mok $7 D016229
650    _2
$a longitudinální studie $7 D008137
650    _2
$a proteiny tau $x mozkomíšní mok $7 D016875
650    _2
$a stárnutí $7 D000375
650    _2
$a biologické markery $x mozkomíšní mok $7 D015415
650    12
$a kognitivní dysfunkce $x diagnóza $7 D060825
650    _2
$a peptidové fragmenty $x mozkomíšní mok $7 D010446
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rakusa, Martin $u Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA $u Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia
700    1_
$a Syrjanen, Jeremy A $u Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a van Harten, Argonde C $u Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
700    1_
$a Lowe, Val J $u Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Jack, Clifford R $u Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Kremers, Walter K $u Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Knopman, David S $u Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Stokin, Gorazd B $u International Clinical Research Center, St. Anne's Hospital, Brno, Czech Republic
700    1_
$a Petersen, Ronald C $u Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA $u Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Vassilaki, Maria $u Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Geda, Yonas E $u Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA $1 https://orcid.org/0000000311877230
773    0_
$w MED00166531 $t Alzheimer's & dementia $x 1552-5279 $g Roč. 19, č. 10 (2023), s. 4498-4506
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35142047 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094430 $b ABA008
999    __
$a ok $b bmc $g 2049674 $s 1210896
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 19 $c 10 $d 4498-4506 $e 20220209 $i 1552-5279 $m Alzheimer's & dementia $n Alzheimers Dement $x MED00166531
GRA    __
$a K01 MH068351 $p NIMH NIH HHS $2 United States
GRA    __
$a R01 AG041851 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG069453 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG034676 $p NIA NIH HHS $2 United States
GRA    __
$a P50 AG016574 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG011378 $p NIA NIH HHS $2 United States
GRA    __
$a R33 AG058738 $p NIA NIH HHS $2 United States
GRA    __
$a R01 NS097495 $p NINDS NIH HHS $2 United States
GRA    __
$a R01 AG057708 $p NIA NIH HHS $2 United States
GRA    __
$a P30 AG019610 $p NIA NIH HHS $2 United States
GRA    __
$a U01 AG006786 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG057708 $p NIA NIH HHS $2 United States
GRA    __
$a U01 AG006786 $p NIA NIH HHS $2 United States
GRA    __
$a P50 AG016574 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG034676 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG011378 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG041851 $p NIA NIH HHS $2 United States
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace